• TLS, TRAF2 Competition, and B-Cell Activation in ESCC

  2026-08-25

  The 2025 Cancer Gene Therapy study links tertiary lymphoid structures with favorable survival in treatment-naïve esophageal squamous cell carcinoma and identifies IRF4-positive B-cell activation as a mechanistic feature. Its central finding is that CD40 and STING compete for TRAF2, coordinating non-canonical NF-κB signaling, STING modification, and IRF4 expression.

• Latent HIV-1, Telomeres, and DNA Damage Vulnerability

  2026-08-25

  The 2018 study by Piekna-Przybylska and Maggirwar shows that HIV-1 infection and latency are associated with telomere elongation in memory CD4+ T cells, while simultaneously increasing sensitivity to telomere-targeting agents. Its findings connect HIV reservoir persistence with altered DNA damage response capacity and suggest a mechanistic basis for selectively stressing infected cells.

• AO/PI and the Translational Logic of Kidney Injury

  2026-08-24

  How AO/PI Staining Solution connects membrane integrity, mechanistic nephropathy research, and more reproducible translational decisions in diabetic kidney disease models.

• Bedaquiline in Viability and TB Assays

  2026-08-23

  This scenario-based guide explains how Bedaquiline (SKU B3492) can support reproducible tuberculosis and cancer-cell experiments while avoiding metabolic-assay misinterpretation. It connects formulation, exposure design, orthogonal readouts, and host-directed tuberculosis research for practical laboratory decision-making.

• NAT1–ENO1–Lactate Axis in Colorectal Cancer

  2026-08-22

  A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator that restrains ENO1 activity, lactate production, and TRAF6-dependent PD-L1 stabilization in colorectal cancer. Its integrated database, multi-omics, patient, cellular, and mouse-model evidence provides a mechanistic rationale for testing lactate-pathway perturbation alongside immune checkpoint blockade, while remaining preclinical.

• hiPSC Intestinal Organoids for Pharmacokinetic Studies

  2026-08-22

  Saito and colleagues developed a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be propagated, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte-associated metabolic and transporter activities, creating a human-relevant platform for pharmacokinetic research.

• PYR-41: E1 Inhibition for Ubiquitination Research

  2026-08-21

  PYR-41 provides an upstream chemical entry point for studying ubiquitin-dependent protein turnover, IκBα stability, inflammatory signaling, and cell survival. This workflow-focused guide explains how to select concentrations, verify E1 engagement, connect results to NF-κB biology, and avoid misinterpreting off-target effects.

• Birinapant (TL32711) in Apoptosis Workflows

  2026-08-20

  Birinapant (TL32711) converts IAP biology into a practical sensitization strategy for apoptosis, TNF signaling, and TRAIL-based cancer assays. This guide connects its mechanism with MDM1–p53 chemoradiotherapy findings and provides workflow parameters, controls, and troubleshooting guidance for translational research.

• Ziprasidone Augmentation in Anxious Depression

  2026-08-20

  This post-hoc analysis examined whether baseline anxious depression moderated the effects of ziprasidone added to escitalopram in patients with major depressive disorder. Depression outcomes did not differ significantly by anxiety subgroup, while the numerical anxiety benefit was not clinically meaningful, underscoring the need to distinguish symptom-domain effects in antidepressant research.

• M344 Histone Deacetylase Inhibitor Workflows

  2026-08-19

  M344 combines cell permeability with potent HDAC inhibition for concentration-response studies, cell differentiation induction, cancer phenotyping, radiation-sensitization experiments, and HIV-1 latency research. This practical guide emphasizes assay controls, soluble stock preparation, orthogonal readouts, and toxicity-aware optimization.

• IBDV VP3 Disrupts IRF7 Antiviral Signaling

  2026-08-19

  A 2025 study identifies the infectious bursal disease virus VP3 protein as a mediator of IRF7 suppression and proteasome-associated IRF7 degradation in chicken cells. The findings connect a viral structural protein with disruption of type I interferon signaling and provide a framework for testing ubiquitination-dependent mechanisms of viral immune evasion.

• Filipin III for Membrane Cholesterol Detection

  2026-08-18

  Filipin III is a polyene macrolide antibiotic that binds membrane cholesterol and supports cholesterol detection in membranes. Its fluorescence behavior, vesicle-lysis selectivity, and compatibility with freeze-fracture electron microscopy make it useful for membrane cholesterol visualization, but the reagent is not a standalone measure of total cholesterol or disease causality.

• HyperScribe™ Poly (A) Tailing Kit

  2026-08-18

  This scenario-driven guide explains how HyperScribe™ Poly (A) Tailing Kit (SKU K1053) can standardize enzymatic polyadenylation of in vitro-transcribed RNA before transfection or micro-injection studies. It connects RNA quality control with more interpretable cell viability, proliferation, and cytotoxicity experiments while clearly separating product specifications from experimental recommendations.

• HDAC Inhibition Enhances Oncolytic HSV in Meningioma

  2026-08-17

  Kawamura and colleagues show that minimally toxic HDAC inhibition substantially improves G47Δ oncolytic herpes simplex virus infectability, intratumoral replication, and killing of malignant meningioma models. The work provides a mechanistic rationale for combining epigenetic modulation with virotherapy while identifying altered mRNA processing and splicing as a possible contributor to the response.

• Adefovir Dipivoxil in Chronic HBV: Evidence and Mechanism

  2026-08-17

  Hadziyannis and Papatheodoridis positioned adefovir dipivoxil as a durable oral option for chronic hepatitis B by integrating its nucleotide-based mechanism with clinical evidence in HBeAg-positive, HBeAg-negative, and lamivudine-resistant disease. The review’s practical importance lies in connecting selective HBV DNA polymerase inhibition with long-term efficacy, low resistance, and the need for renal safety monitoring.

8527 records 1/569 page Next 12345 下5页 Last page